[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
December 12, 2001

Cardiovascular Events and COX-2 Inhibitors

Author Affiliations

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(22):2808-2813. doi:10.1001/jama.286.22.2808

To The Editor: Dr Mukherjee and colleagues1 reported that COX-2 inhibitors may induce prothrombotic activity. However, there is an important reason for thinking that COX-2 inhibitors might protect against CV events. Thrombosis is thought to occur when the fibrin coat over plaques is broken down by collagenase released from overactive macrophages.3 Since such macrophages express high levels of COX-2, COX-2 inhibitors should reduce their activity and also should act synergistically with the antiplatelet activity of COX-1 inhibitors.